Vimarsana
Biggest News Aggregation in the World

Page 9 - B Pfizer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from B Pfizer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In B Pfizer Today - Breaking & Trending Today

Hospitalizations skyrocket in kids too young for COVID-19 shots - Vimarsana News

Hospitalizations skyrocket in kids too young for COVID-19 shots

Hospitalizations of U.S. children under 5 with COVID-19 soared in recent weeks to their highest level since the pandemic began, according to government data released Friday on the only age group not yet eligible for the vaccine.

U.S. urges COVID boosters starting at age 12 to fight omicron - Vimarsana News

U.S. urges COVID boosters starting at age 12 to fight omicron

The U.S. is urging that everyone 12 and older get a COVID-19 booster as soon as they're eligible, to help fight back the hugely contagious omicron mutant that's ripping through the country.

U.S. urges COVID boosters starting at age 12 to fight omicron - Vimarsana News

U.S. urges COVID boosters starting at age 12 to fight omicron

The U.S. is urging that everyone 12 and older get a COVID-19 booster as soon as they're eligible, to help fight back the hugely contagious omicron mutant that's ripping through the country.

LETTERS TO THE EDITOR: Vaccine mandates not about public health - Vimarsana News

LETTERS TO THE EDITOR: Vaccine mandates not about public health

It is too late for the military; too many in the ranks have been vaccinated ("Pentagon goes to court to defend COVID-19 vaccine mandate for troops," Web, Dec. 27). They are all in a vaccine trial, and Pfizer is apparently not going to tell them or anybody else what to expect for at least 55 years.<

Saving lives comes first for drug companies - Vimarsana News

Saving lives comes first for drug companies

In the debate over drug pricing, many believe that drug-makers spend more on advertising than on research and development, and, consequently, that prices can be cut without damaging innovation.